Insider Selling: HilleVax, Inc. (NASDAQ:HLVX) Director Sells 723 Shares of Stock

Posted by William Tyler on May 4th, 2024

HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) Director Aditya Kohli sold 723 shares of HilleVax stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $14.15, for a total value of $10,230.45. Following the sale, the director now owns 782,878 shares in the company, valued at $11,077,723.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Aditya Kohli also recently made the following trade(s):

On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The stock was sold at an average price of $14.03, for a total value of $2,455.25.
On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.44, for a total value of $86,640.00.
On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.93, for a total value of $89,580.00.
On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $164,221.00, for a total value of $985,326,000.00.
On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $17.66, for a total transaction of $105,960.00.
On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $18.66, for a total transaction of $111,960.00.
On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.95, for a total transaction of $113,700.00.
On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.05, for a total transaction of $90,300.00.
On Tuesday, February 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.88, for a total value of $89,280.00.
On Monday, February 12th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.32, for a total value of $91,920.00.

HilleVax Stock Performance

Shares of HLVX traded down $0.41 during mid-day trading on Friday, hitting $13.61. 62,071 shares of the company traded hands, compared to its average volume of 137,172. The stock has a market cap of $676.69 million, a price-to-earnings ratio of -4.60 and a beta of 0.79. The stock has a 50-day moving average price of $15.67 and a two-hundred day moving average price of $14.65. HilleVax, Inc. has a 1 year low of $9.94 and a 1 year high of $20.22. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62.

HilleVax (NASDAQ:HLVX – Get Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.02. Equities analysts anticipate that HilleVax, Inc. will post -3.22 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of HilleVax in a research report on Thursday, March 21st.

Get Our Latest Stock Analysis on HLVX

Institutional Trading of HilleVax

Hedge funds have recently bought and sold shares of the company. Swiss National Bank lifted its stake in shares of HilleVax by 47.2% in the 3rd quarter. Swiss National Bank now owns 31,200 shares of the company’s stock worth $420,000 after purchasing an additional 10,000 shares during the period. StepStone Group LP boosted its stake in shares of HilleVax by 22.2% during the 3rd quarter. StepStone Group LP now owns 826,567 shares of the company’s stock worth $11,117,000 after acquiring an additional 149,998 shares during the last quarter. Maven Securities LTD bought a new stake in shares of HilleVax during the 3rd quarter valued at $478,000. Federated Hermes Inc. increased its stake in shares of HilleVax by 80.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares in the last quarter. Finally, Monashee Investment Management LLC bought a new position in HilleVax in the 3rd quarter worth $1,480,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.